肿瘤细胞治疗研究
英文原题：Optimizing the Efficacy-Toxicity Paradigm in Pediatric Oncology: A Narrative Review of Immunotherapy and Survivorship Outcomes.
免疫治疗改变了结局，但时机至关重要，因为更早应用可显著改善生存。
背景：高收入国家儿童癌症生存率目前接近80%，但多数幸存者终身面临治疗毒性。本综述考察治疗疗效、复发预防与治疗相关并发症之间的关系。 方法：叙述性综合分析2000–2026年具有里程碑意义的儿科肿瘤试验，包括AALL1731（blinatumomab）、ELIANA/PLAT-02（CAR T细胞）和GD2-CART01（神经母细胞瘤），并比较其疗效和毒性。 结果：在AALL1731中，化疗联合blinatumomab使3年无病生存率从87.9%提高至96.0%（HR=0.39，95% CI：0.27–0.56，P<0.001），但脓毒症发生率也从5.1%升至14.8%。比较AALL1731（前线使用blinatumomab）与ELIANA（复发疾病中使用CAR T细胞）显示，较早应用免疫治疗可带来更好结局：两者3年无病生存率分别为96%和48%。在GD2-CART01中，较早使用（此前接受1–2线治疗后）实现5年生存率89%，而延迟使用时为43%（HR=0.31）。约95%的幸存者至少经历1种晚期后遗症，60%–90%成年后仍有慢性疾病。 结论：免疫治疗可显著改变治疗结局，但治疗时机至关重要，较早应用可大幅改善生存。毒性仍普遍存在，需要系统性缓解策略。
BACKGROUND: Childhood cancer survival now approaches 80% in high-income countries, yet most survivors face lifelong toxicity. This review examines the interplay between treatment efficacy, relapse prevention, and therapy-related complications. METHODS: Narrative synthesis of landmark pediatric oncology trials (2000-2026), including AALL1731 (blinatumomab), ELIANA/PLAT-02 (CAR T-cell), and GD2-CART01 (neuroblastoma), with comparative analysis of efficacy and toxicity. RESULTS: In AALL1731, adding blinatumomab to chemotherapy improved 3-year disease-free survival from 87.9% to 96.0% (HR = 0.39, 95% CI: 0.27-0.56, p < 0.001), but increased sepsis from 5.1% to 14.8%. Comparison between AALL1731 (front-line blinatumomab) and ELIANA (CAR T-cell in relapsed disease) reveals that earlier immunotherapy deployment yields better outcomes: 96% DFS vs. 48% 3-year EFS, respectively. In GD2-CART01, early use (after 1-2 prior lines) achieved 89% 5-year survival vs. 43% with delayed use (HR = 0.31). Approximately 95% of survivors experience 1 late effect, with 60-90% carrying chronic conditions into adulthood. CONCLUSIONS: Immunotherapy transforms outcomes, but timing is critical, as earlier deployment dramatically improves survival. Toxicity remains pervasive, requiring systematic mitigation strategies.
MEMBER ACCOUNT
登录成功会直接打开下一页。
